Single versus Double Stenting in NSTEMI Patients with Complex Left Main Bifurcation Disease.

NSTEMI acute coronary syndrome bifurcation stenting left main

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
20 Jun 2022
Historique:
received: 16 05 2022
revised: 13 06 2022
accepted: 19 06 2022
entrez: 24 6 2022
pubmed: 25 6 2022
medline: 25 6 2022
Statut: epublish

Résumé

Background: Among patients with non-ST-segment elevation myocardial infarction (NSTEMI) the presence of a bifurcation left main (LM) disease represents a particular subset graved by both clinical and technical challenges. We sought to assess the long-term outcomes of patients with NSTEMI treated either by single or double stent strategy, having an LM bifurcation culprit lesion. Methods: We retrospectively analyzed the procedural and medical data of consecutive patients referred to our center for NSTEMI due to complex LM bifurcation disease as the culprit lesion, treated using either single or dual stenting (provisional stenting, T or T-and-Protrusion (TAP), Culotte, and Nano-inverted-T (NIT)) techniques between January 2008 and May 2018. Target lesion failure (TLF) was defined as the composite of cardiovascular death, target-vessel myocardial infarction (MI), and clinically driven target lesion revascularization (TLR). Results: Four hundred and forty-five patients (54.1% males, mean age 70.3 ± 12.8 years, mean Syntax score 31.6 ± 6.3) were evaluated. Of these, 155 patients (34.8%) were treated using a single stent while the remaining were treated with a double stent strategy. After a mean follow-up of 37.1 months (IQR 22.1-39.3), TLF rate was 8.7% (n = 39): 5/155 (3.2%) in the crossover group; 10/53 (18.8%) in T/TAP group, 14/89 (15.7%) in the culotte group, and 10/148 (6.7%) in the NIT group of patients. Cardiovascular mortality rate was 2.9% (n = 13) while stent thrombosis was 0.89% (n = 4). On multivariate analysis dyslipidemia, Syntax score > 25, triple vessel disease, additional LM ostial, or LM body lesions and the use of Rotablator, were independent predictors of TLF. Conclusions: Either a single or double stent strategy resulted in low rates of TLF, cardiovascular death, and stent thrombosis in the long-term period in NSTEMI LM patients with contraindications or refusal of surgery. A single stent strategy appeared to have a slightly better outcome compared to a 2-stent strategy.

Identifiants

pubmed: 35743629
pii: jcm11123559
doi: 10.3390/jcm11123559
pmc: PMC9225359
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

EuroIntervention. 2019 May 20;15(1):90-98
pubmed: 31105066
Ann Thorac Surg. 2016 Aug;102(2):573-9
pubmed: 27112651
Am Heart J. 2017 Nov;193:76-83
pubmed: 29129258
Int J Cardiovasc Imaging. 2019 Feb;35(2):207-214
pubmed: 30446919
Eur Heart J. 2019 Jan 14;40(3):237-269
pubmed: 30165617
Int J Cardiovasc Imaging. 2021 Apr;37(4):1107-1119
pubmed: 33200318
Clin Res Cardiol. 2021 Jan;110(1):1-11
pubmed: 32474643
N Engl J Med. 2016 Dec 8;375(23):2223-2235
pubmed: 27797291
Cardiovasc Revasc Med. 2017 Jun;18(4):233-240
pubmed: 28108202
JAMA. 2022 Feb 15;327(7):662-675
pubmed: 35166796
JAMA Intern Med. 2020 Dec 1;180(12):1638-1646
pubmed: 33044497
J Am Coll Cardiol. 2018 Jul 24;72(4):386-398
pubmed: 30025574
EuroIntervention. 2005 Aug;1(2):219-27
pubmed: 19758907
JACC Cardiovasc Interv. 2015 Apr 20;8(4):550-60
pubmed: 25907082
J Am Coll Cardiol. 2017 Nov 28;70(21):2605-2617
pubmed: 29096915
Circulation. 1999 Nov 2;100(18):1872-8
pubmed: 10545431
Rev Esp Cardiol. 2006 Feb;59(2):183
pubmed: 16540043
Cardiovasc Revasc Med. 2018 Oct;19(7 Pt A):751-754
pubmed: 29706477
J Interv Cardiol. 2021 Jan 12;2021:8829686
pubmed: 33519307
Eur Heart J. 2021 Apr 7;42(14):1289-1367
pubmed: 32860058
Catheter Cardiovasc Interv. 2022 Feb;99(3):601-606
pubmed: 33576157
Lancet. 2016 Dec 3;388(10061):2743-2752
pubmed: 27810312
JACC Cardiovasc Interv. 2019 Oct 14;12(19):1927-1937
pubmed: 31521645
JAMA Cardiol. 2019 Feb 1;4(2):100-109
pubmed: 30601910
J Am Coll Cardiol. 2022 Jan 18;79(2):e21-e129
pubmed: 34895950

Auteurs

Gianluca Rigatelli (G)

Cardiovascular Diagnosis and Endoluminal Interventions, Department of Specialistic Medicine, Rovigo General Hospital, 45100 Rovigo, Italy.

Marco Zuin (M)

Department of Translational Medicine, Section of Internal and Cardio-Respiratory Medicine, University of Ferrara, 44121 Ferrara, Italy.

Filippo Gianese (F)

Cardiovascular Diagnosis and Endoluminal Interventions, Department of Specialistic Medicine, Rovigo General Hospital, 45100 Rovigo, Italy.

Dario Adami (D)

Cardiovascular Diagnosis and Endoluminal Interventions, Department of Specialistic Medicine, Rovigo General Hospital, 45100 Rovigo, Italy.

Mauro Carraro (M)

Division of Cardiology, Department of Specialistic Medicine, Rovigo General Hospital, 45100 Rovigo, Italy.

Loris Roncon (L)

Division of Cardiology, Department of Specialistic Medicine, Rovigo General Hospital, 45100 Rovigo, Italy.

Classifications MeSH